- Home
- CURI vs ZNTL Comparison
CURI vs ZNTL Comparison
Compare CURI & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURI | ZNTL |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.5M | 468.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CURI | ZNTL |
|---|---|---|
| Price | $3.35 | $5.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $5.83 | ★ $6.60 |
| AVG Volume (30 Days) | 295.7K | ★ 3.7M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 9.73% | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.52 | N/A |
| Revenue Next Year | $15.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.81 | $1.13 |
| 52 Week High | $7.15 | $6.95 |
Technical Indicators
Market Signals| Indicator | CURI | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 56.39 | 68.58 |
| Support Level | $3.30 | $1.31 |
| Resistance Level | $3.59 | N/A |
| Average True Range (ATR) | 0.14 | 0.65 |
| MACD | 0.04 | 0.33 |
| Stochastic Oscillator | 91.45 | 66.80 |
Price Performance
Historical ComparisonAbout CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. The firm's products and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, and Others. The majority of the revenue comes from the direct business and Content licensing. Geographically, the company generates the majority of its revenue from the United States.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.